



NATIONAL  
QUALITY FORUM

# National Consensus Standards for Patient Safety

*Standing Committee Meeting  
January 23, 2018*

*Andrew Lyzenga  
Jesse Pines  
Kathryn Goodwin  
Hiral Dudhwala  
Desmirra Quinnonez*

# Agenda for the Call

- Disclosures of Interest
- Overview of Evaluation Process
- Consideration of Candidate Measure NQF #3316 Safe Use of Opioids-Concurrent Prescribing
- Public Comment on NQF #3316 Safe Use of Opioids-Concurrent Prescribing
- Prioritization and Feedback of Patient Safety Project Measures
- Public Comment on Prioritization
- Next steps

# Patient Safety Project Team



**Andrew Lyzenga**  
Senior Director



**Jesse Pines**  
Consultant



**Kathryn Goodwin**  
Senior Project Manager



**Hiral Dudhwala**  
Project Manager



**Desmirra Quinnonez**  
Project Analyst

# Introductions and Disclosures of Interest

# Patient Safety Standing Committee

## \* New Committee Members

- Ed Septimus, MD (Co-Chair)
- Iona Thraen, PhD, ACSW (Co-Chair)
- Jason Adelman, MD, MS
- Charlotte Alexander, MD
- Kimberly Applegate, MD, MS, FACR
- Laura Ardizzone, BSN, MS, DNP, CRNA
- Richard Brilli, MD, FAAP, FCCM
- Curtis Collins, PharMD, MS \*
- Christopher Cook, PharmD, PhD
- Melissa Danforth, BA
- Theresa Edelstein, MPH, LNHA
- Lillee Gelinas, MSN, RN, FAAN
- John James, PhD \*
- Stephen Lawless, MD, MBA, FAAP, FCCM
- Lisa McGiffert
- Susan Moffatt-Bruce, MD, PhD
- Patricia Quigley, PhD, MPH, ARNP, CRRN, FAAN, FAANP
- Michelle Schreiber, MD
- Leslie Schultz, PhD, RN, NEA-BC, CPHQ
- Lynda Smirz, M.D., M.B.A.
- Tracy Wang, MPH
- Kendall Webb, MD, FACEP
- Albert Wu, MD, MPH, FACP
- Donald Yealy, MD, FACEP \*
- Yanling Yu, PhD

# Patient Safety Standing Committee Expert Reviewers

- Jamie Roney, DNP, RN-BC, CCRN-K
  - *(Infectious Disease)*
- Pranavi Sreeramoju, MD, MPH, CMQ, FSHEA, FIDSA
  - *(Infectious Disease)*
- Bruno Digiovine, MD
  - *(Pulmonary)*
- Todd Dorman, MD, FCCM
  - *(Pulmonary)*
- Edgar Jimenez, MD, FCCM
  - *(Pulmonary)*
- David Stockwell, MD, MBA
  - *(Pulmonary)*

# Ground Rules for Today's Meeting

## **During the discussions, Committee members should:**

- Be prepared, having reviewed the measures beforehand
- Base evaluation and recommendations on the measure evaluation criteria and guidance
- Remain engaged in the discussion without distractions
- Attend the meeting at all times
- Keep comments concise and focused
- Avoid dominating a discussion and allow others to contribute
- Indicate agreement without repeating what has already been said
- Raise your hand if you want to speak
- Announce your name prior to speaking

# Overview of Evaluation Process



# Roles of the Standing Committee

## *During the Evaluation Meeting*

- Act as a proxy for the NQF multistakeholder membership
- Work with NQF staff to achieve the goals of the project
- Evaluate each measure against each criterion
  - *Indicate the extent to which each criterion is met and rationale for the rating*
- Make recommendations regarding endorsement to the NQF membership
- Oversee portfolio of Patient Safety measures

# Process for Measure Discussion and Voting

- Brief introduction by measure developer (5 minutes)
- Lead discussants will begin Committee discussion for each criterion:
  - *Briefly explaining information on the criterion provided by the developer*
  - *Providing a brief summary of the pre-meeting evaluation comments*
  - *Emphasizing areas of concern or differences of opinion*
  - *Noting, if needed, the preliminary rating by NQF*
    - » This rating is intended to be used as a guide to facilitate the Committee's discussion and evaluation
- Developers will be available to respond to questions at the discretion of the Committee
- Full Committee will discuss, then vote on the criterion, if needed, before moving on to the next criterion

# Endorsement Criteria

- **Importance to measure and report:** Goal is to measure those aspects with greatest potential of driving improvements; if not important, the other criteria are less meaningful (must-pass)
- **Reliability and Validity-scientific acceptability of measure properties:** Goal is to make valid conclusions about quality; if not reliable and valid, there is risk of improper interpretation (must-pass)
- **Feasibility:** Goal is to, ideally, cause as little burden as possible; if not feasible, consider alternative approaches
- **Usability and Use:** Goal is to use for decisions related to accountability and improvement; if not useful, probably do not care if feasible
- **Comparison to related or competing measures**

# Voting on Endorsement Criteria

- **Importance to measure and report (must-pass):**
  - Vote on evidence (if needed) and performance gap
- **Scientific acceptability (must pass):**
  - Vote on reliability and validity (if needed)
- **Feasibility:**
  - Vote on feasibility
- **Usability and Use:**
  - Vote on usability and use
- **Overall Suitability for Endorsement**

If a measure fails on one of the must-pass criteria, there is no further discussion or voting on the subsequent criteria for that measure; we move to the next measure.

# Achieving Consensus

- Quorum: 66% of the Committee
- Pass/Recommended: Greater than 60% “Yes” votes of the quorum (this percent is the sum of high and moderate)
- Consensus not reached (CNR): 40-60% “Yes” votes (inclusive of 40% and 60%) of the quorum
- Does not pass/Not Recommended: Less than 40% “Yes” votes of the quorum
- CNR measures move forward to public and NQF member comment and the Committee will revote

# Committee Quorum and Voting

- If at any point quorum is lost during a meeting, the Committee will continue the measure discussion but will not vote during the meeting. Following the meeting, staff will only send the voting survey to those Committee members who participated in the meeting. Staff will not request votes from any Committee member who did not attend the meeting.
- If staff have to request votes from the Committee following the meeting, Committee member votes must be submitted within 48 hours of the meeting.
- If a Committee member leaves the meeting and quorum is still present, the committee can continue to vote on the measures. The Committee member who left the meeting does not need to vote on the missed measures.

# Questions?

# Consideration of Candidate Measure 3315



## *Review of New Measure*

- NQF #3316 Safe Use of Opioids-Concurrent Prescribing (Centers for Medicare & Medicaid Services)

# Related and Competing Measures

# Related and Competing Measures

- *If a measure meets the four criteria and there are endorsed/new related measures (same measure focus or same target population) or competing measures (both the same measure focus and same target population), the measures are compared to address harmonization and/or selection of the best measure.*

# Public Comment

# Next Steps

# Activities and Timeline

## Cycle 1/Fall 2017

Process Step	Timeline
Post-Meeting Call	February 13, 2018 1:00-3:00 pm EST
Draft Report posted for Public and NQF Member Comment	March 1- 30, 2018
Committee Post-Comment Web Meeting	Tuesday, April 17, 2018 1:00-3:00 pm EST
CSAC Review and Approval	TBD (May/June, 2018)
Appeals	June 6-July 5, 2018

# Activities and Timeline

## Cycle 2/ Spring 2018

Process Step	Timeline
Committee Measure Evaluation Tutorial Web Meeting	Tuesday, May 1, 2018 1-3 pm EST
Committee In-Person Meeting (1 day) NQF Offices, Washington, DC	Tuesday, June 19, 2018
Committee Post-Measure Evaluation Web Meeting	Tuesday, July 10, 2018
Committee Post-Comment Web Meeting	Wednesday, September 12, 2018 1-3 pm EST

# Project Contact Info

- Email: [patientsafety@qualityforum.org](mailto:patientsafety@qualityforum.org)
- NQF Phone: 202-783-1300
- Project page:  
[http://www.qualityforum.org/Patient\\_Safety.aspx](http://www.qualityforum.org/Patient_Safety.aspx)
- SharePoint site:  
[http://share.qualityforum.org/Projects/patient\\_safety/SitePages/Home.aspx](http://share.qualityforum.org/Projects/patient_safety/SitePages/Home.aspx)



THANK YOU